Mann also highlighted the company’s acquisition of South African company Renergen , which he said has a large helium supply. He stated ASP Isotopes is completing “Phase 1C” of the Renergen project and expects that stage to bring the business to positive EBITDA. Mann said the combined plan includes roughly $750 million in funding (about $500 million from the U.S. government and $250 million from a bank loan). He added that the company has said the combined business should achieve more than $300 million in EB ...

Core Insights - ASP Isotopes Inc. has made significant advancements in its business development, including a major supply agreement for enriched silicon-28 and the acquisition of a radiopharmacy in Florida to enhance its operations in nuclear medicine [1][2][3] Supply Agreement for Enriched Silicon-28 - The company has entered into its largest supply contract for enriched silicon-28 with a U.S.-based customer, with deliveries expected in Q1 2026 [2][4] - Enriched silicon-28 is crucial for solid-state quantum computing and advanced semiconductor technologies, providing a noise-free environment for qubits, which enhances device performance [5][6] - The growing demand for high-purity silicon-28 is driven by increased global investment in quantum computing and advanced electronics [6][7] Acquisition of Radiopharmacy - The company has acquired an independent radiopharmacy in Florida, marking PET Labs' first expansion outside South Africa [3][8] - This acquisition aims to enhance PET Labs' nuclear medicine business and is expected to be accretive to revenues, EBITDA, and EPS in 2026 [3][8] - The Florida facility currently offers SPECT services, with plans to introduce PET services by 2027, which is anticipated to boost future revenues and profits [8] Strategic Expansion Plans - The company is pursuing further expansion of PET Labs in the U.S. and other regions to meet the rising demand for radiodiagnostics and radiotherapeutics [9][10] - PET Labs aims to establish a vertically integrated radiopharmacy network capable of producing stable isotopes for radioisotope production, providing a competitive edge in the market [10] - The CEO of PET Labs has indicated plans for both brownfield and greenfield expansions to position the company as a global leader in radioisotope production for oncology treatments [11]